RGX-202

Gene therapy / editing

Phase 2/3topline reported

Evidence outlook · registrational

Duchenne Muscular Dystrophy: topline reported 2026-05-14

No completed mid-stage readout is on record. The sponsor reported topline results on 2026-05-14 (RGX-202 pivotal AFFINITY DUCHENNE Phase 3 topline: primary endpoint met). The announcement is listed under Regulatory events.

Source for the program status

Company guidance: regulatory filing expected next year (REGENXBIO Inc., 5 Nov 2026). “We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Duchenne Muscular Dystrophy
Phase 2 (1)
Other / comorbidity
NCT05983367 · Inspirna, Inc.
2023-10-10 – 2025-03-31 · Colorectal Cancer, Metastatic Colon Cancer
What this study did

Competitive landscape

This drug's own stage for Duchenne Muscular Dystrophy: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RGX-202: this drugPhase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
GivinostatApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
DeramiocelPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Delpacibart ZotadirsenPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
BampidirsenPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication
Nivudirsen (BMN 351)Phase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2026Topline resultRGX-202 pivotal AFFINITY DUCHENNE Phase 3 topline: primary endpoint met
REGENXBIO Inc. · Source ↗